Maintenance treatment with different strategies in advanced non-small-cell lung cancer: A systematic review and meta-analysis

Clinical Lung Cancer

Volumn 14, Issue 4, 2013, Pages 333-341

  Cai, Haoquan ^a   Lin, Yingcheng ^a   Li, Weibing ^b   Li, Xuyuan ^a  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

Continuation maintenance therapy; Non small cell lung cancer; Switch maintenance therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; PLACEBO;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MEDLINE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC;

EID: 84878785241     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.10.010     Document Type: Review

References (41)

1. R. Siegel, D. Naishadham, A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
3. A.G. Pallis, K. Syrigos Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges Cancer Treat Rev 38 2012 861 867
4. T.E. Stinchcombe, M.A. Socinski Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy J Thorac Oncol 4 2009 243 250
5. A. Sandler, R. Gray, M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542-450
6. R. Pirker, J.R. Pereira, A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
7. R. Pirker, J.R. Pereira, J. von Pawel EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 2012 33 42
8. R. Rosell, E. Carcereny, R. Gervais Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
9. C. Zhou, Y.L. Wu, G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
10. Y.H. Kim, M. Mishima Maintenance chemotherapy for non-small-cell lung cancer Cancer Treat Rev 37 2011 505 510
11. A.R. Jadad, R.A. Moore, D. Carroll Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
12. J.F. Tierney, L.A. Stewart, D. Ghersi Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
13. R. Gervais, J.D. Hainsworth, N. Blais Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer Lung Cancer 74 2011 474 480
14. I. Okamoto, K. Takeda, H. Daga Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer Lung Cancer 70 2010 168 173
15. J.D. Patel, T.A. Hensing, A. Rademaker Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer J Clin Oncol 27 2009 3284 3289
16. M. Mencoboni, M. Bergaglio, M. Serra Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer Anticancer Res 27 2007 4425 4429
17. S. Hughes, J. Liong, A. Miah A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study J Thorac Oncol 3 2008 648 651
18. K. Kelly, K. Chansky, L.E. Gaspar Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
19. V. Westeel, E. Quoix, D. Moro-Sibilot Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer J Natl Cancer Inst 97 2005 499 506
20. E.A. Johnson, R.S. Marks, S.J. Mandrekar Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51) Lung Cancer 60 2008 200 207
21. F. Recchia, G. Saggio, A. Nuzzo Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer J Immunother 29 2006 87 94
22. K. Takeda, T. Hida, T. Sato Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203) J Clin Oncol 28 2010 753 760
23. T. Brodowicz, M. Krzakowski, M. Zwitter Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial Lung Cancer 52 2006 155 163
24. C.P. Belani, D.M. Waterhouse, H. Ghazal Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 28 suppl 2010 abstract 7506 www.asco.org Accessed: December 11, 2012
25. F. Barlesi, J. de Castro, V. Dvornichenko AVAPERL (MO22089): final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer randomised to continuation maintenance with bevacizumab or bevacizumab + pemetrexed after first-line bevacizumab-cisplatin-pemetrexed treatment Eur J Cancer 47 suppl 2 2011 abstr LBA34)
26. L. Paz-Ares, F. de Marinis, M. Dediu Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 2012 247 255
27. L. Paz-Ares, F. de Marinis, M. Dediu PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 abstract LBA7507
28. T. Ciuleanu, T. Brodowicz, C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
29. P.M. Fidias, S.R. Dakhil, A.P. Lyss Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer J Clin Oncol 27 2009 591 598
30. F.F. Kabbinavar, V.A. Miller, B.E. Johnson ATLAS investigators overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 28 suppl 15 2010 abstract 7526 www.asco.org Accessed December 11, 2012
31. R.M. Gaafar, V.F. Surmont, G.V. Scagliotti A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) Eur J Cancer 47 2011 2331 2340
32. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
33. L. Zhang, S. Ma, X. Song Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Lancet Oncol 13 2012 466 475
34. M. Perol, C. Chouaid, B.J. Milleron Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study J Clin Oncol 28 suppl 2010 abstract 7507 www.asco.org Accessed December 11, 2012
35. B. Coudert, T. Ciuleanu, K. Park Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy Ann Oncol 23 2012 388 394
36. F. Rinaldi, E. George, P. Clark NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer Lancet Oncol 12 2011 728 730
37. R. Dickson, A. Bagust, A. Boland Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal Pharmacoeconomics 29 2011 1051 1062
38. M.J. Nuijten, J. de Castro Carpeño, C. Chouaid A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer Lung Cancer 76 2012 465 471
39. D.E. Gerber, D.W. Rasco, P. Le Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy J Thorac Oncol 6 2011 365 371
40. D.H. Yoon, S. Baek, C.M. Choi FDG-PET as a potential tool for selecting patients with advanced non-small cell lung cancer who may be spared maintenance therapy after first-line chemotherapy Clin Cancer Res 17 2011 5093 5100
41. J.M. Sun, J.O. Park, Y.W. Won Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy J Thorac Oncol 5 2011 540 545